Prospective audit of a one-centre combined nuchal translucency and triple test programme for the detection of trisomy 21

Prenatal Diagnosis

Volumn 25, Issue 6, 2005, Pages 465-469

  Babbur, Vijayalakshmi ^a   Lees, Christoph C ^a,c   Goodburn, Sandra F ^b   Morris, Nigel ^b   Breeze, Andrew C G ^a   Hackett, Gerald A ^a  

^a Rosie Maternity Hospital   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Down syndrome; Nuchal translucency; Prenatal screening; Serum screening; Trisomy 21

Indexed keywords

ADULT; AGE DISTRIBUTION; AMNIOCENTESIS; ARTICLE; CHORION VILLUS SAMPLING; DOWN SYNDROME; FEMALE; FETUS ECHOGRAPHY; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICAL AUDIT; PREDICTION; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; TRIPLE TEST PROGRAM; TRISOMY 21;

ADULT; ALPHA-FETOPROTEINS; AMNIOCENTESIS; CHORIONIC GONADOTROPIN; CHORIONIC VILLI SAMPLING; DOWN SYNDROME; ESTRIOL; FALSE POSITIVE REACTIONS; FEMALE; GESTATIONAL AGE; HUMANS; MEDICAL AUDIT; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PRENATAL DIAGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 21844473297     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.1163     Document Type: Article

References (22)

1. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K. 2001. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 358: 1665-1667.
2. Cuckle H, Sehmi I. 1999. Calculating correct Down's syndrome risks. Br J Obstet Gynaecol 106: 371-372.
3. Cuckle H, Aitken D, Goodburn S, et al. 2004. Age-standardisation for monitoring performance in Down's syndrome screening programmes. Prenat Diagn 24: 851-856.
4. Forest JC, Masse J, Moutquin JM. 1997. Screening for Down syndrome during first trimester: a prospective study using free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Clin Biochem 30: 333-338.
5. Herman A, Weinraub Z, Dreazen E, et al. 2000. Combined first trimester nuchal translucency and second trimester biochemical screening tests among normal pregnancies. Prenat Diagn 20: 781-784.
6. Hewison J. 2004. Psychological aspects of integrated testing. BJOG 111: 519-520.
7. Kadir RA, Economides DL. 1997. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Ultrasound Obstet Gynecol 9: 244-247.
8. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. 2000. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 96: 207-213.
9. Lam YH, Lee CP, Sin SY, et al. 2002. Comparison and integration of first trimester fetal nuchal translucency and second trimester maternal serum screening for fetal Down syndrome. Prenat Diagn 22: 730-735.
10. Maymon R, Betser M, Dreazen E, Padoa A, Herman A. 2004. A model for disclosing the first trimester part of an integrated Down's syndrome screening test. Clin Genet 65: 113-119.
11. Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, Haddow JE. 1996. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 16: 1115-1119.
12. Nicolaides KH, Azar G, Byrne D, Mansur C, Marks K. 1992. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 304: 867-869.
13. Pajkrt E, van Lith JM, Mol BW, Bleker OP, Bilardo CM. 1998. Screening for Down's syndrome by fetal nuchal translucency measurement in a general obstetric population. Ultrasound Obstet Gynecol 12: 163-169.
14. Schuchter K, Hafner E, Stangl G, Ogris E, Philipp K. 2001. Sequential screening for trisomy 21 by nuchal translucency measurement in the first trimester and maternal serum biochemistry in the second trimester in a low-risk population. Ultrasound Obstet Gynecol 18: 23-25.
15. Snaith V, Howel D, Deverill M, Hewison J, Sturgiss S, Robson S. 2004. The Newcastle randomised controlled trial of early ultrasound screening for fetal abnormality (FA)-termination of pregnancy for FA and psychological consequences. J Obstet Gynaecol 24(Suppl. 1): S19.
16. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13: 231-237.
17. Thilaganathan B, Slack A, Wathen NC. 1997. Effect of first trimester nuchal translucency on second trimester maternal serum biochemical screening for Down's Syndrome. Ultrasound Obstet Gynecol 10: 261-264.
18. Wald NJ, Watt HC, Hackshaw AK. 1999. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. N Engl J Med 341: 461-467.
19. Wapner R, Thom E, Simpson JL, et al. 2003. First-trimester screening for trisomies 21 and 18. N Engl J Med 349: 1405-1413.
20. Weinans MJ, Kooij L, Muller MA, Bilardo KM, Van Lith JM, Tymstra T. 2004. A comparison of the impact of screen-positive results obtained from ultrasound and biochemical screening for Down syndrome in the first trimester: a pilot study. Prenat Diagn 24: 347-351.
21. Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. 2004. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 24: 762-766.
22. Zimmermann R, Hucha A, Savoldelli G, Binkert F, Achermann J, Grudzinskas JG. 1996. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities. Br J Obstet Gynaecol 103: 1009-1014.